Adenovirus vector green light

  • 10:09

Immunicum AB (publ) today announced that the University Hospital in Uppsala has received clearance to initiate a clinical study in patients with neuroendocrine tumors with the Company’s genetically modified adenovirus vector.

Read pressrelease – Immunicum’s adenovirus technology gets green light for clinical study.